Gao, Ronglin
Xu, Xianghuai
Wang, Shengyuan
Pu, Jincheng
Shi, Cuiqin
Wen, Siwan
Zhu, Yiqing
Tang, Jianping
Wang, Xuan
Funding for this research was provided by:
the National Natural Science Foundation of China (82070102)
the National Natural Science Foundation of China (81770097)
the National Natural Science Foundation of China (81801601)
Science and Technology Commission of Shanghai Municipality (20ZR1451500, 20Y11911600)
Article History
Received: 31 August 2021
Accepted: 27 January 2022
First Online: 21 February 2022
Declarations
:
: The study process and the acquisition of informed consent comply with the ethical principles of the Declaration of Helsinki, the relevant GCP requirements, and the laws related to drug and data protection of China. Written informed consent will be obtained from all participants. The medical ethics committee of Shanghai Tongji Hospital have approved the trial (ethical approval number 2021-006), and the study has been registered on the Chinese Clinical Trials database, ID ChiCTR2100045202.
: Not applicable.
: The authors declare that they have no competing interests.